NASDAQ
150.42USD
-3.10 (-2.02%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.2B
P/E
—
EPS
—
Beta
-0.17
52W range
46.08-161.38
Day range
149.05–154.56
Open
152.36
Prev close
153.52
Volume
144.5K
Avg volume
242K
Dividend
0.00
IPO
2015-01-02
https://seekingalpha.com/article/4938046-palvella-therapeutics-q2-first-approval-could-unlock-a-rare-disease-commercial-flywheel · 8/19/2026+0.90
https://www.fool.com/coverage/filings/2026/06/27/what-to-know-about-this-usd476-000-palvella-therapeutics-insider-sale-after-a-620-stock-rally/ · 6/27/2026+0.80
https://seekingalpha.com/article/4912224-palvella-stock-qtorin-continues-making-progress-so-i-remain-bullish · 6/5/2026+0.80
https://www.globenewswire.com/news-release/2026/05/20/3298897/0/en/palvella-therapeutics-presents-new-selva-and-toiva-data-at-the-2026-international-society-for-the-study-of-vascular-anomalies-world-congress-supporting-qtorin-rapamycin-as-a-potent.html · 5/20/2026+1.00
https://www.globenewswire.com/news-release/2026/03/30/3264521/0/en/Palvella-Therapeutics-Announces-Scientific-Publication-in-Journal-of-Vascular-Anomalies-Highlighting-the-Infiltrative-Growth-and-Therapeutic-Challenges-of-Microcystic-Lymphatic-Mal.html · 3/30/2026+0.80
https://www.fool.com/coverage/filings/2026/03/25/palvella-stock-up-340-as-insider-sells-shares-here-s-what-the-move-does-and-does-not-signal/ · 3/25/2026+0.80
https://www.fool.com/coverage/filings/2026/03/24/director-buys-usd500-000-worth-of-palvella-therapeutics-shares-after-phase-3-win/ · 3/24/2026+1.00
https://www.globenewswire.com/news-release/2025/09/03/3143473/0/en/Palvella-Therapeutics-Strengthens-Leadership-with-Appointment-of-Accomplished-Scientist-and-Biopharmaceutical-Executive-David-W-Osborne-Ph-D-as-Chief-Innovation-Officer.html · 9/3/2025+0.80
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
